NovoCure Ltd. (NVCR)
Market Closed
15 Oct, 08:00 PM
$
14. 41
+0.57
+4.1185%
$
1.61B Market Cap
- P/E Ratio
- Div Yield
1.69M Volume
-2.03 Eps
$ 13.84
Previous Close 
Want to track NVCR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript
NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Ingrid Goldberg - Investor Relations Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Larry Biegelsen - Wells Fargo Jessica Fye - J.P. Morgan Vijay Kumar - Evercore ISI Emily Bodnar - H.C.
Seekingalpha | 2 years ago
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.
Zacks | 2 years ago
2026 © Marketlog. All Rights Reserved.
